Bumpus Namandje sold $16K of RXRX

Bumpus Namandje sold 4,386 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.54 on 2026-06-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bumpus Namandje
Published Jun 4, 2026, 9:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 4, 2026, 9:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
medium confidence
Mentioned
$RXRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The disclosure provides incremental information about insider liquidity, but does not, by itself, change Recursion’s fundamentals or near-term catalysts.

02

Market read

A single director sale at a specific price is unlikely to drive a durable repricing absent other company news.

03

What to watch

Traders may over-weight Form 4 prints; without accompanying news (trial, financing, guidance), the signal-to-noise is low.

Relevance 6/10Novelty 6/10Timing: Filed today; sale executed on 2026-06-03

Background

SEC Form 4 reports insider transactions; this one is a director open-market sale executed under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

Recursion Pharmaceuticals disclosed a director open-market sale of 4,386 shares at $3.54 under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is an ownership-change disclosure (Form 4) with a stated pre-arranged 10b5-1 plan, which reduces interpretability versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated operational/regulatory/clinical linkage.

None indicated.

None indicated.

Counterpoint

Because the sale is pre-arranged under 10b5-1, it can reflect routine liquidity rather than bearish expectations; price may ignore it.

Key entities

  • Recursion Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Bumpus Namandje

    Director who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$RXRXMed

Recursion Aligns With FDA On Phase 3 Trial Design For FAP Drug REC-4881; Stock Up

Recursion Pharmaceuticals (RXRX) aligned with the FDA on the Phase 3 trial design for REC-4881, an oral MEK1/2 inhibitor for familial adenomatous polyposis (FAP). The trial, expected to start in late 2027, will assess composite event-free survival as the primary endpoint. REC-4881 has shown a 47% median reduction in total polyp burden in Phase 1b/2 trials. RXRX shares were up 4.41% in premarket trading.

$RXRXMedAI 8/10

Recursion (RXRX) Q3 2026 Earnings Call Transcript

Recursion (RXRX) reported Q3 2026 earnings, highlighting clinical data for REC-4881 and REC-1245. REC-4881 showed significant reductions in polyp burden and safety. REC-1245 demonstrated early activity in solid tumors. The company secured $535M in partner cash inflows and extended cash runway to 2029. Operating expenses for 2026 were lowered to $375M, with 2027 expected under $360M. Sanofi and Roche collaborations advanced, with milestones and royalties. Fred Hassan was appointed board chair.

$RXRXMedAI 8/10

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals (RXRX) reported Q3 updates, including 55% and 50% median reductions in upper and lower GI polyp burdens, respectively. REC-1245 showed partial responses in advanced solid tumors. Sanofi exercised an option, triggering a $10M payment. RXRX raised $200M in financing, extending cash runway into 2029. The company expects to start a registrational study in 2H 2027.

$RXRXHighAI 8/10

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

Recursion Pharmaceuticals reported a narrower-than-expected Q3 2026 loss of 22 cents per share, with revenues of $18.55 million, up 258.5% YoY, driven by a $10 million Sanofi milestone payment. Operating expenses declined, and the company advanced its pipeline, including REC-4881 and REC-1245. RXRX shares are down 6.4% YTD.